Vitamin D₃ supplementation works. It increases gut absorption of calcium and phosphorus, supports bone mineral density, and corrects clinical deficiency. The mechanism is well-characterized and the benefits are real.
What's less well-known: D₃ alone may also drive calcium into places you don't want it. Specifically, into the lining of arteries and the kidneys. The fix isn't to take less D₃ — it's to pair D₃ with the cofactor that determines where the calcium ends up.
The calcium-routing problem
The calcium-routing problem
When D₃ raises serum calcium, the body has to direct that calcium somewhere. The desired destination is bone matrix — calcium that strengthens the skeleton and resists osteoporosis. The undesired destinations are arterial walls (where calcium deposits contribute to atherosclerosis) and renal tubules (where they form kidney stones).
Two K₂-dependent proteins decide that routing:
Osteocalcin is produced by osteoblasts. K₂ activates osteocalcin via gamma-carboxylation; activated osteocalcin binds calcium and incorporates it into hydroxyapatite — the mineral phase of bone. Without K₂, osteocalcin remains uncarboxylated and can't perform this routing function.
Matrix Gla-protein (MGP) is the second K₂-dependent protein. MGP lives in vascular smooth muscle and connective tissue, where its job is to prevent calcium deposition outside of bone. Like osteocalcin, MGP requires K₂ for gamma-carboxylation to be functional.
What the data shows
What the data shows
Observational studies of high-dose D₃ supplementation without K₂ have repeatedly found increased coronary artery calcium scores over 2–5 year follow-up periods. Conversely, populations with high dietary K₂ intake — Japanese consumers of natto, certain fermented dairy regions — show lower arterial calcification rates even when serum 25-OH-D is high.
The intervention data, while still emerging, points the same direction. A 3-year RCT (Knapen et al., 2015) found that MK-7 supplementation alone reduced arterial stiffness in healthy postmenopausal women. Combined with adequate vitamin D status, the effect appears additive.
How Samnel pairs them
How Samnel pairs them
Our Adult D₃+K₂ capsule contains a single daily serving of Calcifediol paired with 180 µg of MK-7 (vitamin K₂ as menaquinone-7). MK-7 was selected over the shorter-chain MK-4 because of its longer serum half-life — roughly 72 hours versus MK-4's 2 hours — which means daily dosing maintains stable activated-protein levels.
The K₂ inclusion isn't there to make the bottle look more impressive. It's there because activating Calcifediol without activating the proteins that direct its calcium is, at best, half a strategy.
